Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP515 in non-alcoholic fatty liver disease
NCT07308548Phase 2Recruiting
- Sponsor
- Hinova Pharmaceuticals Inc.
- Start
- Oct 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HP515 in non-alcoholic fatty liver disease (NAFLD), sponsored by Hinova Pharmaceuticals Inc.. Started Oct 2025; status: recruiting.
02
Drugs
HP515
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT07308548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07308548.